Carbamoylcholine

Carbamoylcholine

SCHEMBL547970

C[N+](C)(C)CCOC(N)=O.Cl.[Cl-]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM3

The experimentally established mechanism targets of Carbamoylcholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 known ✓ P20309 6/20 0.95
CHRM5 P08912 6/20 0.95
CHRM1 P11229 6/20 0.95
CHRM2 P08172 5/20 0.95
CHRM4 P08173 5/20 0.95
CHRNB2 P17787 4/20 0.91
CHRNA4 P43681 4/20 0.91
CHRNA7 P36544 3/20 0.91
HTR1A P08908 2/20 0.91
LMNA P02545 2/20 0.91
CYP2C19 P33261 2/20 0.91
TSHR P16473 1/20 0.91
MAPT P10636 1/20 0.61
BLM P54132 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.58
ADRA2A P08913 1/20 0.58
ADRA1A P35348 1/20 0.58
PGR P06401 1/20 0.58
TBXA2R P21731 1/20 0.58
CHRNB4 P30926 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbamoylcholine SCHEMBL27544830 0.98 CHRM5 (0.91) CHRM5CHRM1CHRM3CHRM2CHRM4
Carbamoylcholine SCHEMBL21067459 0.98 CHRM1 (0.95) CHRM5CHRM1CHRM3CHRM2CHRM4
Carbamoylcholine SCHEMBL4727962 0.98 CHRM1 (0.95) CHRM5CHRM1CHRM3CHRM2CHRM4
Carbamoylcholine SCHEMBL2791 0.98 CHRM5 (1.00) CHRM5CHRM1CHRM3CHRM2CHRM4
Carbamoylcholine SCHEMBL5060882 0.98 CHRM5 (1.00) CHRM5CHRM1CHRM3CHRM2CHRM4
Carbamoylcholine SCHEMBL9792915 0.95 CHRM1 (0.91) CHRM5CHRM1CHRM3CHRM2CHRM4
Carbamoylcholine SCHEMBL21433743 0.95 CHRM1 (0.91) CHRM5CHRM1CHRM3CHRM2CHRM4
Carbamoylcholine SCHEMBL15094513 0.95 CHRM5 (0.95) CHRM5CHRM1CHRM3CHRM2CHRM4
Carbamoylcholine SCHEMBL21197429 0.95 CHRM5 (0.95) CHRM5CHRM1CHRM3CHRM2CHRM4
Carbamoylcholine SCHEMBL9109254 0.95 CHRM5 (0.95) CHRM5CHRM1CHRM3CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5908866-A VISION DEFECTS ASTRA AKTIEBOLAG (SE) 1999-06-01 US claimed
EP-0661968-B1 PHARMACEUTICAL COMPOSITION CONTAINING CARBACHOL AND OTHER CHOLINERGIC SUBSTANCES ASTRA AB (SE) 1998-10-14 EP claimed
US-5679713-A TOPICAL TREATMENT OF DRY EYE DISEASE (KERATOCONJUNCTIVITIS SICCA) IN HUMAN AND OTHER MAMMALS ASTRA AKTIEBOLAG (SE) 1997-10-21 US claimed
EP-0661968-A1 PHARMACEUTICAL COMPOSITION CONTAINING CARBACHOL AND OTHER CHOLINERGIC SUBSTANCES Astra Aktiebolag (SE) 1995-07-12 EP claimed
WO-1993003718-A1 PHARMACEUTICAL COMPOSITION CONTAINING CARBACHOL AND OTHER CHOLINERGIC SUBSTANCES AKTIEBOLAGET ASTRA (SE) 1993-03-04 WO claimed
EP-0528776-A1 Pharmaceutical composition containing carbachol and other cholinergic substances AKTIEBOLAGET ASTRA (SE) 1993-02-24 EP claimed
EP-4727533-A2 SYNTHESIS OF 2-(CARBAMOYLOXY)-N,N,N-TRIMETHYLETHAN-1-AMINIUM SALTS Visus Therapeutics, Inc. (US) 2026-04-22 EP disclosed
US-20250221923-A1 BOOSTING OSMOTIC BLOOD-ORGAN BARRIER OPENING FOR IMPROVED DELIVERY OF THERAPEUTICS TO ORGANS UNIVERSITY OF MARYLAND, BALTIMORE 2025-07-10 US disclosed
WO-2024259258-A2 SYNTHESIS OF 2-(CARBAMOYLOXY)-N,N,N-TRIMETHYLETHAN-1-AMINIUM SALTS VISUS THERAPEUTICS, INC. (US) 2024-12-19 WO disclosed
CN-119053608-A Novel compound, conjugated polymer, method for producing same, composition for film formation, organic thin film, and organic semiconductor element 东曹株式会社 2024-11-29 CN disclosed
US-20240009269-A1 MEMBRANE-ACTIVE PEPTIDES AND METHODS FOR REVERSIBLE BLOOD- BRAIN BARRIER OPENING THE JOHNS HOPKINS UNIVERSITY (US) 2024-01-11 US disclosed
EP-3597262-B1 FORMULATION FOR INTRACUTANEOUS INJECTION XERIS PHARMACEUTICALS INC (US) 2023-12-27 EP disclosed
US-20220296736-A1 ADMINISTRATION OF THERAPEUTIC AGENTS TO BRAIN AND OTHER CELLS AND TISSUE THE JOHNS HOPKINS UNIVERSITY (US) 2022-09-22 US disclosed
US-5010056-A Growth disorders PIERREL SPA (IT) 1991-04-23 US disclosed
EP-0301392-A1 Pharmaceutical composition for intranasal administration comprising GH - Releasing hormone, a cholinergic agonist and in case a bile salt Pierrel S.p.A. (IT) 1989-02-01 EP disclosed
US-4459309-A Compositions and methods of lowering intraocular pressure in the hypertensive mammalian eye THE TEXAS A&M UNIVERSITY SYSTEM (US) 1984-07-10 US disclosed
EP-0051604-A1 COMPOSITIONS AND METHODS OF LOWERING INTRAOCULAR PRESSURE IN THE HYPERTENSIVE MAMMALIAN EYE CHIOU, George C.Y. (US) 1982-05-19 EP disclosed
WO-1981003123-A1 COMPOSITIONS AND METHODS OF LOWERING INTRAOCULAR PRESSURE IN THE HYPERTENSIVE MAMMALIAN EYE CHIOU G 1981-11-12 WO disclosed
EP-0004835-B1 ETHANOLAMINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR MEDICINAL USE Aktiebolaget DRACO (SE) 1981-10-14 EP disclosed
US-4171353-A Immunization of animals using choline esters as an immunological adjuvant RYAN WAYNE L 1979-10-16 US disclosed